Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Core Viewpoint - Aytu BioPharma, Inc. has successfully extended the method of use patent for its EXXUA product, which is significant for its market position and future revenue potential [1] Company Summary - Aytu BioPharma, Inc. focuses on developing innovative medicines aimed at treating complex central nervous system diseases, with the goal of improving patient quality of life [1] - The patent extension for EXXUA (gepirone) is now valid until September 2, 2030, providing a longer period of market exclusivity [1] Industry Summary - The pharmaceutical industry is characterized by the importance of patent protection, which plays a critical role in maintaining competitive advantages and ensuring revenue streams for companies [1]